Summarized by Masters of Longevity from PR Newswire.
Phase III trial data report that a B7-H3-directed antibody-drug conjugate notably extended survival compared with standard chemotherapy in relapsed small-cell lung cancer patients.
Key Takeaways
- Median overall survival was 18.5 months with the antibody-drug conjugate versus 10.3 months with topotecan.
- The investigational drug reduced risk of death by 54% compared with topotecan (HR 0.46; P<0.0001).
- Objective response rate was 58.3% versus 12.6% and median progression-free survival was 7.2 versus 3.0 months.
